First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

por Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Renee Commerford, S., Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Publicado 2018